Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer

doi: 10.1007/s00262-014-1624-x

Figure Lengend Snippet: Dynamic changes in IL-33 and ST2 transcripts along the colorectal adenoma–carcinoma sequence. The quantitative real-time PCR results showed that the expression of IL-33 mRNA was significantly increased to a ~ninefold higher level in adenoma tissues (gray bar in a); it was also higher in sporadic CRC tissues (black bar in a) than in normal controls (white bar in a), but significantly lower compared with the adenomas. The expression of ST2 mRNA in adenoma tissues was increased to a ~threefold higher level and slightly increased in CRC tissues compared with normal controls (b). (Y axes in a, b are fold changes relative to normal controls; P values are derived from the Mann–Whitney test.)

Article Snippet: The following primary antibodies were used: goat antihuman IL-33 polyclonal antibody (working dilution 1:100; R&D systems, Minneapolis, MN, USA) and mouse antihuman ST2 monoclonal antibody (working dilution 1:100; Medical & Biological Laboratories Co. Ltd., Nagoya, Japan).

Techniques: Sequencing, Real-time Polymerase Chain Reaction, Expressing, Derivative Assay, MANN-WHITNEY

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer

doi: 10.1007/s00262-014-1624-x

Figure Lengend Snippet: Kaplan–Meier curves of overall survival differences among patients with sporadic CRC. The Kaplan–Meier analysis shows that the expression levels of IL-33 (a) and ST2 (b) do not predicate the overall survival time in patients with sporadic CRC (both P values determined by the log-rank test)

Article Snippet: The following primary antibodies were used: goat antihuman IL-33 polyclonal antibody (working dilution 1:100; R&D systems, Minneapolis, MN, USA) and mouse antihuman ST2 monoclonal antibody (working dilution 1:100; Medical & Biological Laboratories Co. Ltd., Nagoya, Japan).

Techniques: Expressing

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer

doi: 10.1007/s00262-014-1624-x

Figure Lengend Snippet: Photograph presentations of IL-33 and its receptor, ST2, in the tumor stroma and the adenomatous/cancerous epithelium. Immunohistochemical (IHC) results show that IL-33 immunoreactivity was not observed in the normal epithelium, and a low density of IL-33-positive cells was found in the lamina propria in the control (a). In both the adenoma and CRC, IL-33 immunoreactivity was frequently observed in tumor-associated microvessels (arrow in b, c) and adenomatous/cancerous epithelium (arrow in b for adenoma and inserted image in 3C for CRC). ST2 immunoreactivity was observed in both the epithelium (arrow head) and microvessels (arrow) in all three groups (d for control, e for adenoma and f for CRC). (a–e IHC, counterstained with hematoxylin, original magnification 200×.)

Article Snippet: The following primary antibodies were used: goat antihuman IL-33 polyclonal antibody (working dilution 1:100; R&D systems, Minneapolis, MN, USA) and mouse antihuman ST2 monoclonal antibody (working dilution 1:100; Medical & Biological Laboratories Co. Ltd., Nagoya, Japan).

Techniques: Immunohistochemical staining

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer

doi: 10.1007/s00262-014-1624-x

Figure Lengend Snippet: Density grading scores of IL-33- and ST2-positive cells in adenomas and CRC tissues. The semi-quantitative results showed that the density of IL-33-positive cells in the adenomatous epithelium (gray bar in a) was higher than in the controls. The density of IL-33-positive cells was also higher in the CRC epithelium (black bar in a) compared with the controls, but lower than the adenomatous epithelium (Fig. a). The density of IL-33-positive stromal cells was increased in the adenoma stroma, with a smaller increase in magnitude of density in the CRC stroma (b). The density of ST2-positive cells in the adenomatous epithelium was non-statistically increased and was unchanged in the CRC cancerous epithelium (c). The density of ST2-positive cells in the stroma showed a gradually increasing trend from the control to adenoma to CRC, but these differences were not statistically significant (d). To examine the expression of IL-33/ST2 in endothelial cells, the number of IL-33-positive tumors associated with microvessel density (MVD) and the number of ST2-positive tumors associated with MVD were counted. The results show that the IL-33-positive MVD was significantly increased in the adenoma stroma and non-statistically increased in the CRC tumor stroma compared with normal lamina propria (e). The number of ST2-positive microvessels was greatly increased in both the adenoma stroma and the CRC tumor stroma compared with the normal lamina propria (f). (HPF high-power field.)

Article Snippet: The following primary antibodies were used: goat antihuman IL-33 polyclonal antibody (working dilution 1:100; R&D systems, Minneapolis, MN, USA) and mouse antihuman ST2 monoclonal antibody (working dilution 1:100; Medical & Biological Laboratories Co. Ltd., Nagoya, Japan).

Techniques: Expressing

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer

doi: 10.1007/s00262-014-1624-x

Figure Lengend Snippet: Phenotypic characterization of IL-33-expressing cells in the adenoma and CRC tumor stromas. Double IHC with IL-33/CD34 and IL-33/SMA-alpha revealed that an increase in IL-33-positive cells (red) in the adenoma and CRC tumor stromas was frequently co-localized with CD34-labeled microvessels (blue) (b, c) and SMA-alpha-labeled myofibroblasts (blue) (e, f) compared with the normal lamina propria (a, d). (a–f double IHC, original magnification 400×; counterstaining was not applied.)

Article Snippet: The following primary antibodies were used: goat antihuman IL-33 polyclonal antibody (working dilution 1:100; R&D systems, Minneapolis, MN, USA) and mouse antihuman ST2 monoclonal antibody (working dilution 1:100; Medical & Biological Laboratories Co. Ltd., Nagoya, Japan).

Techniques: Expressing, Labeling